

# **GUIDELINE WATCH (SEPTEMBER 2009): PRACTICE GUIDELINE FOR THE TREATMENT OF PATIENTS WITH SCHIZOPHRENIA**

*Lisa Dixon, M.D.*

*Diana Perkins, M.D.*

*Christine Calmes, Ph.D.*

APA's *Practice Guideline for the Treatment of Patients With Schizophrenia, Second Edition*, was published in April 2004 (1). This watch highlights key research studies published since that date. The studies were identified by a MEDLINE literature search for meta-analyses and randomized, controlled trials published between 2002 and 2008, using the same key words used for the literature search performed for the 2004 guideline.

With regard to pharmacotherapy, there have been several important randomized trials of antipsychotics. For chronic schizophrenia, trials include the National Institute of Mental Health (NIMH) Clinical Antipsychotic Trial for Intervention Effectiveness (CATIE) and the United Kingdom–funded Cost Utility of the Latest Antipsychotics in Schizophrenia (CUtLASS). For first-episode schizophrenia, there are two industry-funded trials, the European First Episode Schizophrenia Trial

(EUFEST)—funded by AstraZeneca, Pfizer, and Sanofi-Aventis—and the Comparison of Atypicals for First Episode Schizophrenia (CAFE)—funded by AstraZeneca. For early-onset schizophrenia, there is one trial, the NIMH-funded Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS). These trials point to a reconsideration of treatment with the antipsychotics perphenazine and molindone and by extension other first-generation antipsychotics, with the possible exception of haloperidol, for which some trials have shown greater rates of extrapyramidal side effects or less favorable clinical response (2). In addition, a recent population-based cohort study (3) that encompassed 11 years of follow-up showed decreased rates of mortality with perphenazine as compared with other first- and second-generation antipsychotic agents; only clozapine use was associated with lower rates of overall mortality.

For the period April 2008 to August 2009, Dr. Dixon reports attending a consultation meeting for Janssen and receiving a grant from Bristol-Meyers-Squibb for investigator-initiated research, Dr. Perkins reports receiving research funding from Janssen (ended January 2009) and reports receiving income for consulting for Dainippon (data safety monitoring board on lurasidone studies) and for serving on speakers bureaus for Eli Lilly, and Dr. Calmes reports no competing interests. The Executive Committee on Practice Guidelines reviewed this watch and found no evidence of influence from these relationships.

The American Psychiatric Association's (APA's) practice guidelines are developed by expert work groups using an explicit methodology that includes rigorous review of available evidence, broad peer review of iterative drafts, and formal approval by the APA Assembly and Board of Trustees. APA practice guidelines are intended to assist psychiatrists in clinical decision making. They are not intended to be a standard of care.

The ultimate judgment regarding a particular clinical procedure or treatment plan must be made by the psychiatrist in light of the clinical data presented by the patient and the diagnostic and treatment options available. Guideline watches summarize significant developments in practice since publication of an APA practice guideline. Watches may be authored and reviewed by experts associated with the original guideline development effort and are approved for publication by APA's Executive Committee on Practice Guidelines. Thus, watches represent opinion of the authors and approval of the Executive Committee but not policy of the APA. This guideline watch was published in September 2009. Copyright © 2009. American Psychiatric Association. All rights reserved.

In addition, randomized controlled trials have demonstrated the safety and efficacy of a new antipsychotic, paliperidone, leading to its approval by the U.S. Food and Drug Administration (FDA). Several controlled clinical trials have investigated treatments to prevent or treat antipsychotic-related weight gain and metabolic changes. Additionally, there have been promising clinical trials of bupropion and behavioral interventions to reduce smoking in schizophrenia patients.

With regard to psychosocial treatments, new studies lend some additional support to the treatments recommended in the 2004 guideline. In addition, combinations of treatments have begun to be tested to enhance supported employment and social skills training. An evidence base has developed for interventions for obesity and for smoking cessation. There also has been continued study of cognitive remediation and peer support and peer-delivered services, which have the potential to play a useful role in recovery.

## PHARMACOTHERAPY

---

### COMPARATIVE EFFECTIVENESS OF ANTIPSYCHOTICS

The 2004 guideline recommends that selection of an antipsychotic agent be guided by the patient's past medication history, current symptoms and co-occurring conditions, other concurrent treatments, and preferences. The guideline states that second-generation agents should be considered first-line options for patients in the acute phase, mainly because of the decreased risk of extrapyramidal side effects and tardive dyskinesia, but acknowledges debate over the relative advantages, disadvantages, and cost-effectiveness of first- and second-generation agents. The guideline also states that for some patients, a first-generation agent may be an appropriate first-line option. This latter recommendation has been strengthened by the results of several recently published effectiveness studies that suggest that the first-generation antipsychotics perphenazine and molindone may be equally effective as second-generation agents. In fact, the distinction between first- and second-generation antipsychotics appears to have limited clinical utility.

Phase I of the double-blind CATIE clinical trial randomized 1,490 patients to available FDA-approved second-generation antipsychotics—risperidone, olanzapine, quetiapine, and ziprasidone—and to the first-generation antipsychotic perphenazine (4). There were few exclusion criteria, and patients were recruited from diverse programs in order to include “real-world” patients with potential co-occurring psychiatric or general medical conditions. The primary outcome measure was discontinuation from the randomized treatment, and by the end of the 18-month trial 74% of patients had switched to another antipsychotic or discontinued treatment. Olanzapine was the most effective medication, with 64% discontinuing, compared with the discontinuation rates for risperidone (74%) and quetiapine (82%). Perphenazine discontinuation rates (75%) were comparable to the other second-generation antipsychotics, including ziprasidone (79%).

A similar pattern of results was found when symptom outcomes or hospitalization rates were examined. Extrapyramidal side effects were uncommon and similar across drugs, but olanzapine carried the greatest burden of metabolic side effects.

In the CUtLASS trial (5), 227 patients with schizophrenia who were judged by their treating clinician to potentially benefit from a new antipsychotic medication trial “because of inadequate response or adverse effects” were randomized to receive either a first- or a second-generation (excluding clozapine) antipsychotic. The specific antipsychotic was chosen by the treating clinician. The primary outcome measure, assessed by blind raters at 12, 26, and 56 weeks, was “quality of life,” reflecting social and vocational function. Symptom changes were secondary outcomes. There was no difference in any outcome measures between groups.

In the EUFEST trial (6), 498 patients experiencing their first episode of schizophrenia were randomized to receive haloperidol, amisulpride, olanzapine, quetiapine, or ziprasidone. The study was conducted at 50 sites in 13 European countries and Israel, and treatment was not blinded. The primary outcome measure was discontinuation from treatment. At 1-year follow-up, all-cause discontinuation was higher for haloperidol (72%) than that for amisulpride (40%), olanzapine (33%), quetiapine (53%), or ziprasidone (45%). Global ratings of symptoms were least improved by treatment with quetiapine or haloperidol and most improved by treatment with amisulpride; however, there were no differences in symptom improvement as measured by the Positive and Negative Syndrome Scale or in rates of hospital admission. Extrapyramidal side effects were most severe in patients treated with haloperidol, and weight gain was most severe in patients treated with olanzapine.

In the CAFE trial (7), 400 patients early in the course of psychotic illness were randomly assigned in a double-

blind manner to receive olanzapine, quetiapine, or risperidone. At 1-year follow-up, all-cause discontinuation rates were similar for all groups (68.4%–71.4%), and there was no difference in symptom severity measures. Side effects were common and in line with the known side-effect profile of these antipsychotics.

The TEOSS study (8) was a double-blind, randomized trial comparing olanzapine, risperidone, and molindone in 119 pediatric patients with early-onset schizophrenia and schizoaffective disorder. “Response” was defined as improvement on the Clinical Global Impression scale of “very much” or “much” improved, at least a 20% reduction in symptom severity as measured by the Positive and Negative Syndrome Scale, and tolerating treatment for at least 8 weeks. A significant difference in response likelihood was not found between groups (molindone 50%, olanzapine 34%, risperidone 46%). Treatment with risperidone and olanzapine was associated with significant weight gain and metabolic side effects, and patients treated with molindone were more likely to report akathisia.

## PALIPERIDONE

Paliperidone, marketed in an extended-release (ER) formulation, is the major active metabolite (9-hydroxy-risperidone) of risperidone. It is mainly cleared by the kidneys, with negligible hepatic metabolism. Five randomized, double-blind trials, sponsored by the manufacturer, Janssen Pharmaceuticals, involving 1,647 acutely ill patients with schizophrenia, demonstrated paliperidone ER to have greater efficacy than placebo at a fixed dose over 6 weeks (9) and led to the medication receiving FDA approval in 2006. Side effects included marked prolactin elevation in men and women, a greater incidence of extrapyramidal side effects at higher doses (>6 mg/day), dose-related weight gain, and tachycardia. Comparisons with fixed-dose (10 mg/day) olanzapine ( $N=1,332$ ) showed similar efficacy and less liability for weight gain but greater liability for extrapyramidal side effects. Paliperidone ER thus appears to have a similar side-effect profile to its parent compound, risperidone. The relative advantages or disadvantages of paliperidone compared with risperidone are unknown.

## MANAGING SIDE EFFECTS OF ANTIPSYCHOTIC MEDICATIONS

As described in the 2004 guideline, weight gain and metabolic side effects are common or frequent adverse effects of the second-generation antipsychotics clozapine, olanzapine, risperidone, and quetiapine. The guideline recommends regular monitoring of weight, body mass index, serum lipids,

and fasting glucose levels of all patients. When patients gain weight, it is recommended that clinicians discuss treatment options, which may include switching medications, to prevent further weight gain and encourage weight loss.

Several clinical trials have investigated pharmacological and cognitive-behavioral treatments that may attenuate or reverse antipsychotic-related weight gain and lipid, glucose, and insulin changes (10). The nonpharmacological weight management interventions are described in greater detail in the subsection “Psychosocial Interventions for Weight Management,” later in this watch. There have been several pharmacological clinical trials investigating metformin (a peripheral insulin-sensitizing agent), topiramate (an anticonvulsant), reboxetine (a selective norepinephrine reuptake inhibitor), and amantadine (a dopamine agonist). Metformin has been investigated in five randomized controlled studies, with four showing some indication of benefits (11–14), and one negative trial (15). The most promising results were reported in a randomized, double-blind trial in which 128 olanzapine-treated first-episode patients received adjunctive metformin 750 mg/day, metformin 750 mg/day plus lifestyle changes, lifestyle changes plus placebo, or placebo (11). The patients who received adjunctive metformin plus lifestyle changes had the most robust weight loss, body mass index (BMI) reduction, waist circumference reduction, and fasting insulin and insulin-resistance level reduction; these outcomes were significantly better than lifestyle changes plus placebo or placebo alone. For example, BMI significantly decreased by 1.8 units on average in the metformin plus lifestyle changes group, by 1.2 units in the metformin alone group, and by 0.5 units in the lifestyle changes plus placebo group. In the placebo group, in contrast, BMI increased by an average of 0.7 units. No increase in adverse events, including nausea, occurred in the patients treated with metformin.

Two randomized, placebo-controlled trials of adjunctive topiramate have reported weight loss in overweight patients who were already receiving treatment with olanzapine (16) or with risperidone, olanzapine, quetiapine, or clozapine (17). In patients who had gained weight during olanzapine treatment, two randomized, placebo-controlled trials reported that further weight gain was less pronounced with adjunctive amantadine treatment (18, 19). Two randomized, placebo-controlled trials also reported significant attenuation of weight gain when adjunctive reboxetine was initiated concomitantly with olanzapine in patients with a first episode of schizophrenia (20, 21). However, the clinical utility of these adjunctive treatments is unclear, given their relatively small impact on weight as well as their cost, potential side effects, and potential interactions with other medications.

## PSYCHOSOCIAL TREATMENTS

---

As described in the 2004 guideline, psychosocial treatments such as family intervention, supported employment, assertive community treatment, skills training, and cognitive-behavioral therapy (CBT) can prevent relapse and enable recovery during the stable phase of treatment. Some interventions, such as family psychoeducation, may also be initiated during the acute phase. “Recovery,” a construct that overlaps with but differs from treatment goals of cure or remission of symptoms, is defined by the President’s New Freedom Commission on Mental Health as the “process in which people are able to live, work, learn, and participate fully in their communities” (22). The Substance Abuse and Mental Health Services Administration (23) has identified 10 components of recovery: “self-direction; individualized and person-centered; empowerment; holistic; non-linear; strengths-based; peer support; respect; responsibility; and hope.” These components refer to the nature of treatment and the individual experience of the recovery process.

### FAMILY PSYCHOEDUCATION

The 2004 guideline recommends engaging and collaborating with family members during an acute episode, whether first episode or relapse. Studies cited in the guideline and more recent studies have shown that family psychoeducation, delivered for 6–9 months following recent illness exacerbation or hospitalization, including family support, education, access to providers during crises, and some type of problem-solving skills, can reduce relapse rates among persons with schizophrenia as well as reduce family burden (24). Other studies that have focused on individuals who have not had an illness exacerbation have found that family psychoeducation contributed to improved social and vocational outcomes for individuals with schizophrenia and lower levels of distress and increased perceptions of professional and social support among family members (25, 26). Family psychoeducation programs lasting less than 6 months have been shown to contribute to positive outcomes for patients, including increased treatment adherence (27), and for family members, including increased knowledge about schizophrenia and improved family relationships (28–30).

### ASSERTIVE COMMUNITY TREATMENT

Studies have continued to demonstrate that assertive community treatment (ACT) results in reduced hospital-

ization rates and reduced homelessness (31–34), particularly among individuals with high rates of hospitalization (35). Interventions that show higher fidelity to the ACT model show stronger outcomes (35).

### SUPPORTED EMPLOYMENT

Recent studies of supported employment offer further evidence for its role in helping individuals with schizophrenia obtain competitive employment, earn more wages, and work more hours (36–38). Employment outcomes are better when there is greater fidelity to the supported employment model (39–41). Recent studies of supported employment have focused on improving long-term job retention and economic independence by augmenting supported employment with cognitive remediation (42, 43), social skills training (44, 45), and CBT (46, 47).

### COGNITIVE-BEHAVIORAL THERAPY

Recent studies continue to offer support for the role of CBT in reducing both positive and negative symptoms (48–51) and improving social functioning (52). However, there is not consistent evidence that CBT improves outcomes among individuals who are experiencing acute psychotic symptoms (52–54). A recent meta-analysis suggests that CBT can be delivered in both individual and group formats with similar benefits, improving overall outcome in patients with schizophrenia who have residual symptoms (55).

### SOCIAL SKILLS TRAINING

Similar to supported employment, social skills training assumes that recovery requires a multifaceted approach. Recent studies suggest that skills training contributes to improvements in broader functional outcomes (24, 56) and has been shown to lead to improved skills in refusing drugs of abuse (57), as well as improved communication in the workplace (44, 45) and with health care professionals (58). More recently, social skills training has been combined with family interventions (59, 60), case management (58), and CBT (61). There have been attempts to facilitate generalization of skills training to real world settings through application of skills training outside of the therapeutic context (58, 62). Skills training has evolved into so-called illness management and recovery programs (63).

## COGNITIVE REMEDIATION

The 2004 guideline characterizes cognitive remediation as a variety of experimental treatments addressing the cognitive deficits associated with schizophrenia. A large number of studies on these approaches have been conducted over the last 5 years. This emerging literature continues to be limited by the wide variation in cognitive targets, small sample sizes, and a tendency for outcomes to be performance on neuropsychological tests rather than functional status or even symptoms. Studies using cognitive remediation in combination with vocational rehabilitation to enhance work functioning (42, 47, 64–66) have yielded positive findings, but more research is needed.

## PEER SUPPORT AND PEER-DELIVERED SERVICES

A critical part of the emerging focus on recovery has been recognition of the importance of enhancing the role of individuals who have mental illness in the delivery of services and in roles in which the value of this experience is appreciated as therapeutic. Programs have been developed in which individuals with serious mental illness deliver traditional services, either as paid staff or as volunteers, as well as provide support to other individuals with serious mental illness. Peer-to-peer services include in-person self-help groups, Internet support groups, peer-delivered services, peer-run or peer-operated services, peer partnerships, and peer employees (67). Davidson et al. (68) outline three types of peer programs: mutual support, participation in peer-run programs, and the use of individuals with severe mental illness as a source of support and services for other individuals with severe mental illness.

When the evidence base for peer-delivered services is being considered, it is important to note a critical disconnect between these types of programs and traditional diagnostic-driven treatment systems. Peer-based programs and services tend to discount or deemphasize formal psychiatric diagnoses. Therefore, the formal psychiatric diagnoses of persons served in these studies may be unknown. A majority of randomized trials that compare peer-delivered with non-peer-delivered services do not show differences on most outcome measures (69–72). It is notable that despite the lack of significant group differ-

ences in these randomized, controlled trials, participants improved over the course of their participation in peer-delivered services (70, 71). Studies have shown that the delivery of peer-based services is feasible despite the fact that the precise benefits of peer-delivered services are as yet uncertain because of poorly defined comparison groups, small sample sizes, and the heterogeneity of outcomes. Future work needs to focus on either documenting advantages to consumer-delivered services or identifying the positive effect on standard clinical outcomes (e.g., symptoms, hospitalization) or other dimensions, such as increased self-esteem, social support, and progress toward recovery.

## PSYCHOSOCIAL INTERVENTIONS FOR WEIGHT MANAGEMENT

Several clinical trials have investigated pharmacological and cognitive-behavioral treatments that may attenuate or reverse antipsychotic-related weight gain and lipid, glucose, and insulin changes (10). Several recently published randomized, controlled trials investigating psychoeducation and behavioral interventions for weight loss for individuals with schizophrenia found support for modest weight loss (mean weight loss across seven studies was 5.8 lbs) (11, 73–81). Moreover, recent reviews and meta-analyses further support the use of a psychoeducation or cognitive-behavioral intervention to promote weight loss among individuals with schizophrenia who are overweight or have experienced antipsychotic-related weight gain (82–85). Two studies also found support for psychoeducation and behavioral interventions in the prevention of weight gain among individuals with schizophrenia who had recently begun taking antipsychotic medications (86, 87). Despite these positive findings, it should be noted that retention of weight loss was either not measured or problematic in many of the aforementioned investigations. Moreover, there is marked variability across studies in terms of treatment modality and length and format of treatment. It appears that individuals with schizophrenia can successfully participate in weight loss interventions. Future investigations should target weight loss retention strategies and weight prevention interventions.

## SUBSTANCE USE DISORDERS

---

APA's 2007 *Practice Guideline for the Treatment of Patients With Substance Use Disorders, Second Edition* (88) reviews newer literature available on the treatment of substance

use disorders, including among individuals with schizophrenia. Important developments in this area are highlighted in the following subsections.

## SMOKING

As noted in the 2004 guideline, smoking cessation is a critical health challenge for individuals with schizophrenia. Smoking treatments include nicotine replacement therapies (NRTs), bupropion, and psychosocial approaches (88).

Recent studies have examined combined pharmacological and psychosocial approaches in individuals with schizophrenia. For example, Baker et al. (89) found higher abstinence rates among smokers with psychotic disorders who were enrolled in an 8-session behavioral/motivational enhancement intervention combined with NRT relative to those in routine care over a 12-month period. Several randomized, placebo-controlled trials suggest that bupropion (90), bupropion plus NRT (91, 92), and bupropion plus a cognitive-behavioral intervention (93) significantly improve the likelihood of smoking reduction or smoking cessation among individuals with schizophrenia. However, the fact that these studies found significant rates of relapse following study termination suggests that smokers with schizophrenia may require more extended pharmacological treatment in combination with continuous and active support for smoking cessation. Bupropion is FDA approved for the treatment of smoking cessation and thus can be recommended as an intervention for smoking cessation for individuals with schizophrenia. Varenicline is also FDA approved for the treatment of smoking cessation but has not been studied in a randomized fashion among individuals with schizophrenia. With bupropion and varenicline treatment, a recent FDA boxed warning has highlighted a potential for serious neuropsychiatric symptoms, including changes in behavior, hostility, agitation, depressed mood, suicidal thoughts and behavior, and attempted suicide (94).

Research on psychosocial interventions suggests that smokers with schizophrenia will attend psychosocial smoking cessation programs, that interventions can have some benefit in terms of smoking reduction, and that, for those who attend, quitting is possible (89). Programs designed for individuals with schizophrenia may need to include extended outreach to improve treatment engagement and retention, training in coping skills that can be used to manage negative affect in place of smoking, and other strategies that can overcome some of the common barriers to smoking cessation found among this group of smokers.

## OTHER SUBSTANCE USE DISORDERS

Recent studies suggest that a motivational intervention designed for individuals with schizophrenia and substance use disorders may improve substance use and psychiatric

outcomes for individuals with a dual diagnosis. Two recent studies found that brief interventions incorporating motivational and behavioral techniques to treat substance use disorders contributed to reductions in substance use among individuals with schizophrenia spectrum diagnoses (95, 96). Specifically, Graeber et al. (95) found higher abstinence rates among individuals with schizophrenia and alcohol use disorders who were involved in a three-session motivational enhancement program relative to those involved in an educational intervention. Similarly, James et al. (96) found that individuals involved in a six-session, manualized group intervention with motivational enhancement and relapse prevention showed greater improvements in drug-related consequences and reductions in marijuana, alcohol, and polydrug use at follow-up relative to individuals who attended a one-session drug education class. Sigmon and Higgins (97) used a within-subjects reversal design to test the impact of a voucher-based contingent reinforcement intervention to reduce marijuana use in seven participants (86% having a schizophrenia diagnosis). Participants completed 4 weeks of baseline monitoring, during which they received \$10 vouchers per urine specimen independent of result, followed by 12 weeks of intervention, during which they received \$10 per urine specimen that was negative for marijuana, followed by another 4 weeks of baseline monitoring. The percentage of negative tests was significantly greater during the intervention weeks. However, two studies did not find that involvement in a substance use intervention contributed to lower rates of substance use (98, 99). Although there is variability in research methodology and findings, motivational and behavioral interventions targeting substance use for individuals with dual diagnoses appear to be feasible and beneficial.

## REFERENCES

1. American Psychiatric Association: Practice guideline for the treatment of patients with schizophrenia, second edition. *Am J Psychiatry* 2004; 161:1–56
2. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM: Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. *Lancet* 2009; 373:31–41
3. Tiihonen J, Lonnqvist J, Wahlbeck K, Klaukka T, Niskanen L, Tanskanen A, Haukka J: 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). *Lancet* 2009; Jul 10 [Epub ahead of print]
4. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. *N Engl J Med* 2005; 353:1209–1223

5. Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayward KP, Murray RM, Markwick A, Lewis SW: Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). *Arch Gen Psychiatry* 2006; 63:1079–1087
6. Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, Gheorghe MD, Rybakowski JK, Galderisi S, Libiger J, Hummer M, Dollfus S, Lopez-Ibor JJ, Hranov LG, Gaebel W, Peuskens J, Lindfors N, Riecher-Rossler A, Grobbee DE: Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. *Lancet* 2008; 371:1085–1097
7. McEvoy JP, Lieberman JA, Perkins DO, Hamer RM, Gu H, Lazarus A, Sweitzer D, Olexy C, Weiden P, Strakowski SD: Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. *Am J Psychiatry* 2007; 164:1050–1060
8. Sikich L, Frazier JA, McClellan J, Findling RL, Vitiello B, Ritz L, Ambler D, Puglia M, Maloney AE, Michael E, De Jong S, Slifka K, Noyes N, Hlastala S, Pierson L, McNamara NK, Delpuerto-Bedoya D, Anderson R, Hamer RM, Lieberman JA: Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the Treatment of Early Onset Schizophrenia Spectrum Disorders (TEOSS) study. *Am J Psychiatry* 2008; 165:1420–1431
9. Nussbaum AM, Stroup TS: Paliperidone for treatment of schizophrenia. *Schizophr Bull* 2008; 34:419–422
10. Baptista T, Elfakih Y, Uzcategui E, Sandia I, Talamo E, Araujo dB, Beaulieu S: Pharmacological management of atypical antipsychotic-induced weight gain. *CNS Drugs* 2008; 22:477–495
11. Wu RR, Zhao JP, Jin H, Shao P, Fang MS, Guo XF, He YQ, Liu YJ, Chen JD, Li LH: Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial. *JAMA* 2008; 299:185–193
12. Wu RR, Zhao JP, Guo XF, He YQ, Fang MS, Guo WB, Chen JD, Li LH: Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study. *Am J Psychiatry* 2008; 165:352–358
13. Klein DJ, Cottingham EM, Sorter M, Barton BA, Morrison JA: A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents. *Am J Psychiatry* 2006; 163:2072–2079
14. Baptista T, Rangel N, Fernandez V, Carrizo E, El Fakih Y, Uzcategui E, Galeazzi T, Gutierrez MA, Servigna M, Davila A, Uzcategui M, Serrano A, Connell L, Beaulieu S, de Baptista EA: Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled trial. *Schizophr Res* 2007; 93:99–108
15. Baptista T, Martinez J, Lacruz A, Rangel N, Beaulieu S, Serrano A, Arape Y, Martinez M, de Mendoza S, Teneud L, Hernandez L: Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial. *Can J Psychiatry* 2006; 51:192–196
16. Nickel MK, Nickel C, Muehlbacher M, Leiberich PK, Kaplan P, Lahmann C, Tritt K, Krawczyk J, Kettler C, Egger C, Rother WK, Loew TH: Influence of topiramate on olanzapine-related adiposity in women: a random, double-blind, placebo-controlled study. *J Clin Psychopharmacol* 2005; 25:211–217
17. Ko YH, Joe SH, Jung IK, Kim SH: Topiramate as an adjuvant treatment with atypical antipsychotics in schizophrenic patients experiencing weight gain. *Clin Neuropharmacol* 2005; 28:169–175
18. Graham KA, Gu H, Lieberman JA, Harp JB, Perkins DO: Double-blind, placebo-controlled investigation of amantadine for weight loss in subjects who gained weight with olanzapine. *Am J Psychiatry* 2005; 162:1744–1746
19. Deberdt W, Winokur A, Cavazzoni PA, Trzaskoma QN, Carlson CD, Bymaster FP, Wiener K, Floris M, Breier A: Amantadine for weight gain associated with olanzapine treatment. *Eur Neuropsychopharmacol* 2005; 15:13–21
20. Poyurovsky M, Isaacs I, Fuchs C, Schneidman M, Faragian S, Weizman R, Weizman A: Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study. *Am J Psychiatry* 2003; 160:297–302
21. Poyurovsky M, Fuchs C, Pashinian A, Levi A, Faragian S, Maayan R, Gil-Ad I: Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study. *Psychopharmacology (Berl)* 2007; 192:441–448
22. New Freedom Commission on Mental Health: Achieving the Promise: Transforming Mental Health Care in America. Final Report. DHHS Pub. No. SMA-03–3832. Rockville, MD, 2003
23. Substance Abuse and Mental Health Services Administration: National Consensus Statement on Mental Health Recovery U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Center for Mental Health Services. <http://mentalhealth.samhsa.gov/publications/allpubs/sma05-4129/>, 2005
24. Pfammatter M, Junghan UM, Brenner HD: Efficacy of psychological therapy in schizophrenia: conclusions from meta-analyses. *Schizophr Bull* 2006; 32 Suppl 1:S64–S80
25. Magliano L, Fiorillo A, Malangone C, De Rosa C, Maj M: Patient functioning and family burden in a controlled, real-world trial of family psychoeducation for schizophrenia. *Psychiatr Serv* 2006; 57:1784–1791
26. Hazel NA, McDonnell MG, Short RA, Berry CM, Voss WD, Rodgers ML, Dyck DG: Impact of multiple-family

- groups for outpatients with schizophrenia on caregivers' distress and resources. *Psychiatr Serv* 2004; 55:35–41
27. Pitschel-Walz G, Bauml J, Bender W, Engel RR, Wagner M, Kissling W: Psychoeducation and compliance in the treatment of schizophrenia: results of the Munich Psychosis Information Project Study. *J Clin Psychiatry* 2006; 67:443–452
  28. Pickett-Schenk SA, Bennett C, Cook JA, Steigman P, Lippincott R, Villagrancia I, Grey D: Changes in caregiving satisfaction and information needs among relatives of adults with mental illness: results of a randomized evaluation of a family led education intervention. *Am J Orthopsychiatry* 2006; 76:545–553
  29. Pickett-Schenk SA, Cook JA, Steigman P, Lippincott R, Bennett C, Grey DD: Psychological well-being and relationship outcomes in a randomized study of family led education. *Arch Gen Psychiatry* 2006; 63:1043–1050
  30. Pickett-Schenk SA, Lippincott RC, Bennett C, Steigman PJ: Improving knowledge about mental illness through family led education: the journey of hope. *Psychiatr Serv* 2008; 59:49–56
  31. Coldwell CM, Bender WS: The effectiveness of assertive community treatment for homeless populations with severe mental illness: a meta-analysis. *Am J Psychiatry* 2007; 164:393–399
  32. Nelson G, Aubry T, Lafrance A: A review of the literature on the effectiveness of housing and support, assertive community treatment, and intensive case management interventions for persons with mental illness who have been homeless. *Am J Orthopsychiatry* 2007; 77:350–361
  33. Ben-Porath DD, Peterson G, Piskur C: Effectiveness of and consumer satisfaction with an assertive community treatment program for the severely mentally ill: a 3-year follow-up. *Psychological Services* 2004; 1:40–47
  34. Morse GA, Calsyn RJ, Dean KW, Helminiak TW, Wolff N, Drake RE, Yonker RD, Lama G, Lemming MR, McCudden S: Treating homeless clients with severe mental illness and substance use disorders: costs and outcomes. *Community Ment Health J* 2006; 42:377–404
  35. Burns T, Catty J, Dash M, Roberts C, Lockwood A, Marshall M: Use of intensive case management to reduce time in hospital in people with severe mental illness: systematic review and meta-regression. *BMJ* 2007; 335:336
  36. Cook JA, Lehman AF, Drake R, McFarlane WR, Gold PB, Leff HS, Blyler C, Toprac MG, Razzano LA, Burke-Miller JK, Blankertz L, Shafer M, Pickett-Schenk SA, Grey DD: Integration of psychiatric and vocational services: a multi-site randomized, controlled trial of supported employment. *Am J Psychiatry* 2005; 162:1948–1956
  37. Gold PB, Meisler N, Santos AB, Carnemolla MA, Williams OH, Keleher J: Randomized trial of supported employment integrated with assertive community treatment for rural adults with severe mental illness. *Schizophr Bull* 2006; 32:378–395
  38. Twamley EW, Padin DS, Bayne KS, Narvaez JM, Williams RE, Jeste DV: Work rehabilitation for middle-aged and older people with schizophrenia: a comparison of three approaches. *J Nerv Ment Dis* 2005; 193:596–601
  39. Becker DR, Xie H, McHugo GJ, Halliday J, Martinez RA: What predicts supported employment program outcomes? *Community Ment Health J* 2006; 42:303–313
  40. Catty J, Lissouba P, White S, Becker T, Drake RE, Fioritti A, Knapp M, Lauber C, Rossler W, Tomov T, van Busschbach J, Wiersma D, Burns T: Predictors of employment for people with severe mental illness: results of an international six-centre randomised controlled trial. *Br J Psychiatry* 2008; 192:224–231
  41. McGrew JH, Griss ME: Concurrent and predictive validity of two scales to assess the fidelity of implementation of supported employment. *Psychiatr Rehabil J* 2005; 29:41–47
  42. McGurk SR, Mueser KT, Feldman K, Wolfe R, Pascaris A: Cognitive training for supported employment: 2–3 year outcomes of a randomized controlled trial. *Am J Psychiatry* 2007; 164:437–441
  43. Wexler BE, Bell MD: Cognitive remediation and vocational rehabilitation for schizophrenia. *Schizophr Bull* 2005; 31:931–941
  44. Mueser KT, Aalto S, Becker DR, Ogden JS, Wolfe RS, Schiavo D, Wallace CJ, Xie H: The effectiveness of skills training for improving outcomes in supported employment. *Psychiatr Serv* 2005; 56:1254–1260
  45. Wallace CJ, Tauber R: Supplementing supported employment with workplace skills training. *Psychiatr Serv* 2004; 55:513–515
  46. Lysaker PH, Bond G, Davis LW, Bryson GJ, Bell MD: Enhanced cognitive-behavioral therapy for vocational rehabilitation in schizophrenia: effects on hope and work. *J Rehabil Res Dev* 2005; 42:673–682
  47. Vauth R, Corrigan PW, Clauss M, Dietl M, Dreher-Rudolph M, Stieglitz RD, Vater R: Cognitive strategies versus self-management skills as adjunct to vocational rehabilitation. *Schizophr Bull* 2005; 31:55–66
  48. Turkington D, Kingdon D, Weiden PJ: Cognitive behavior therapy for schizophrenia. *Am J Psychiatry* 2006; 163:365–373
  49. Turkington D, Kingdon D, Rathod S, Hammond K, Pelton J, Mehta R: Outcomes of an effectiveness trial of cognitive-behavioural intervention by mental health nurses in schizophrenia. *Br J Psychiatry* 2006; 189:36–40
  50. Turkington D, Sensky T, Scott J, Barnes TR, Nur U, Siddle R, Hammond K, Samarasekera N, Kingdon D: A randomized controlled trial of cognitive-behavior therapy for persistent symptoms in schizophrenia: a five-year follow-up. *Schizophr Res* 2008; 98:1–7
  51. Trower P, Birchwood M, Meaden A, Byrne S, Nelson A, Ross K: Cognitive therapy for command hallucinations: randomised controlled trial. *Br J Psychiatry* 2004; 184:312–320
  52. Startup M, Jackson MC, Bendix S: North Wales randomized controlled trial of cognitive behaviour therapy for acute schizophrenia spectrum disorders: outcomes at 6 and 12 months. *Psychol Med* 2004; 34:413–422



53. Bechdolf A, Knost B, Kuntermann C, Schiller S, Klosterkotter J, Hambrecht M, Pukrop R: A randomized comparison of group cognitive-behavioural therapy and group psychoeducation in patients with schizophrenia. *Acta Psychiatr Scand* 2004; 110:21–28
54. Garety PA, Fowler DG, Freeman D, Bebbington P, Dunn G, Kuipers E: Cognitive-behavioural therapy and family intervention for relapse prevention and symptom reduction in psychosis: randomised controlled trial. *Br J Psychiatry* 2008; 192:412–423
55. Wykes T, Steel C, Everitt B, Tarrier N: Cognitive behavior therapy for schizophrenia: effect sizes, clinical models, and methodological rigor. *Schizophr Bull* 2008; 34:523–537
56. Kurtz MM, Mueser KT: A meta-analysis of controlled research on social skills training for schizophrenia. *J Consult Clin Psychol* 2008; 76:491–504
57. Bellack AS, Bennett ME, Gearon JS, Brown CH, Yang Y: A randomized clinical trial of a new behavioral treatment for drug abuse in people with severe and persistent mental illness. *Arch Gen Psychiatry* 2006; 63:426–432
58. Bartels SJ, Forester B, Mueser KT, Miles KM, Dums AR, Pratt SI, Sengupta A, Littlefield C, O'Hurley S, White P, Perkins L: Enhanced skills training and health care management for older persons with severe mental illness. *Community Ment Health J* 2004; 40:75–90
59. Kopelowicz A, Zarate R, Gonzalez S, V, Mintz J, Liberman RP: Disease management in Latinos with schizophrenia: a family assisted, skills training approach. *Schizophr Bull* 2003; 29:211–227
60. Valencia M, Rascon ML, Juarez F, Murow E: A psychosocial skills training approach in Mexican out-patients with schizophrenia. *Psychol Med* 2007; 37:1393–1402
61. Granholm E, McQuaid JR, McClure FS, Auslander LA, Perivoliotis D, Pedrelli P, Patterson T, Jeste DV: A randomized, controlled trial of cognitive behavioral social skills training for middle-aged and older outpatients with chronic schizophrenia. *Am J Psychiatry* 2005; 162:520–529
62. Moriana JA, Alarcon E, Herruzo J: In-home psychosocial skills training for patients with schizophrenia. *Psychiatr Serv* 2006; 57:260–262
63. Hasson-Ohayon I, Roe D, Kravetz S: A randomized controlled trial of the effectiveness of the illness management and recovery program. *Psychiatr Serv* 2007; 58:1461–1466
64. Bell MD, Bryson GJ, Greig TC, Fiszdon JM, Wexler BE: Neurocognitive enhancement therapy with work therapy: productivity outcomes at 6- and 12-month follow-ups. *J Rehabil Res Dev* 2005; 42:829–838
65. Bell M, Fiszdon J, Greig T, Wexler B, Bryson G: Neurocognitive enhancement therapy with work therapy in schizophrenia: 6-month follow-up of neuropsychological performance. *J Rehabil Res Dev* 2007; 44:761–770
66. McGurk SR, Mueser KT, Pascaris A: Cognitive training and supported employment for persons with severe mental illness: one-year results from a randomized controlled trial. *Schizophr Bull* 2005; 31:898–909
67. Solomon P: Peer support/peer provided services underlying processes, benefits, and critical ingredients. *Psychiatr Rehabil J* 2004; 27:392–401
68. Davidson L, Chinman M, Sells D, Rowe M: Peer support among adults with serious mental illness: a report from the field. *Schizophr Bull* 2006; 32:443–450
69. Castelein S, Bruggeman R, van Busschbach JT, van der GM, Stant AD, Kneegtering H, Wiersma D: The effectiveness of peer support groups in psychosis: a randomized controlled trial. *Acta Psychiatr Scand* 2008; 118:64–72
70. Davidson L, Shahar G, Stayner DA, Chinman MJ, Rakfeldt J, Tebes JK: Supported socialization for people with psychiatric disabilities: lessons from a randomized controlled trial. *J Community Psychol* 2004; 32:453–477
71. Rivera JJ, Sullivan AM, Valenti SS: Adding consumer-providers to intensive case management: does it improve outcome? *Psychiatr Serv* 2007; 58:802–809
72. Sells D, Davidson L, Jewell C, Falzer P, Rowe M: The treatment relationship in peer-based and regular case management for clients with severe mental illness. *Psychiatr Serv* 2006; 57:1179–1184
73. Brar JS, Ganguli R, Pandina G, Turkoz I, Berry S, Mahmoud R: Effects of behavioral therapy on weight loss in overweight and obese patients with schizophrenia or schizoaffective disorder. *J Clin Psychiatry* 2005; 66:205–212
74. Kwon JS, Choi JS, Bahk WM, Yoon KC, Hyung KC, Chul SY, Park BJ, Geun OC: Weight management program for treatment-emergent weight gain in olanzapine-treated patients with schizophrenia or schizoaffective disorder: a 12-week randomized controlled clinical trial. *J Clin Psychiatry* 2006; 67:547–553
75. Weber M, Wyne K: A cognitive/behavioral group intervention for weight loss in patients treated with atypical antipsychotics. *Schizophr Res* 2006; 83:95–101
76. Poulin MJ, Chaput JP, Simard V, Vincent P, Bernier J, Gauthier Y, Lanctot G, Saindon J, Vincent A, Gagnon S, Tremblay A: Management of antipsychotic-induced weight gain: prospective naturalistic study of the effectiveness of a supervised exercise programme. *Aust N Z J Psychiatry* 2007; 41:980–989
77. Khazaal Y, Fresard E, Rabia S, Chatton A, Rothen S, Pomini V, Grasset F, Borgeat F, Zullino D: Cognitive behavioural therapy for weight gain associated with antipsychotic drugs. *Schizophr Res* 2007; 91:169–177
78. Mauri M, Simoncini M, Castrogiovanni S, Iovieno N, Cecconi D, Dell'Agnello G, Quadrigli M, Rossi A, Donda P, Fagiolini A, Cassano GB: A psychoeducational program for weight loss in patients who have experienced weight gain during antipsychotic treatment with olanzapine. *Pharmacopsychiatry* 2008; 41:17–23
79. Jean-Baptiste M, Tek C, Liskov E, Chakunta UR, Nicholls S, Hassan AQ, Brownell KD, Wexler BE: A pilot study of a weight management program with food provision in schizophrenia. *Schizophr Res* 2007; 96:198–205

80. Wu MK, Wang CK, Bai YM, Huang CY, Lee SD: Outcomes of obese, clozapine-treated inpatients with schizophrenia placed on a six-month diet and physical activity program. *Psychiatr Serv* 2007; 58:544–550
81. Brown S, Chan K: A randomized controlled trial of a brief health promotion intervention in a population with serious mental illness. *Journal of Mental Health* 2006; 15:543–549
82. Faulkner G, Cohn T, Remington G: Interventions to reduce weight gain in schizophrenia. *Cochrane Database Syst Rev* 2007;CD005148
83. Alvarez-Jimenez M, Hetrick SE, Gonzalez-Blanch C, Gleeson JF, McGorry PD: Non-pharmacological management of antipsychotic-induced weight gain: systematic review and meta-analysis of randomised controlled trials. *Br J Psychiatry* 2008; 193:101–107
84. Loh C, Meyer JM, Leckband SG: A comprehensive review of behavioral interventions for weight management in schizophrenia. *Ann Clin Psychiatry* 2006; 18:23–31
85. Faulkner G, Cohn TA: Pharmacologic and nonpharmacologic strategies for weight gain and metabolic disturbance in patients treated with antipsychotic medications. *Can J Psychiatry* 2006; 51:502–511
86. Evans S, Newton R, Higgins S: Nutritional intervention to prevent weight gain in patients commenced on olanzapine: a randomized controlled trial. *Aust N Z J Psychiatry* 2005; 39:479–486
87. Alvarez-Jimenez M, Gonzalez-Blanch C, Vazquez-Barquero JL, Perez-Iglesias R, Martinez-Garcia O, Perez-Pardal T, Ramirez-Bonilla ML, Crespo-Facorro B: Attenuation of antipsychotic-induced weight gain with early behavioral intervention in drug-naive first-episode psychosis patients: a randomized controlled trial. *J Clin Psychiatry* 2006; 67:1253–1260
88. American Psychiatric Association: Treatment of patients with substance use disorders, second edition. *Am J Psychiatry* 2007; 164:5–123
89. Baker A, Richmond R, Haile M, Lewin TJ, Carr VJ, Taylor RL, Jansons S, Wilhelm K: A randomized controlled trial of a smoking cessation intervention among people with a psychotic disorder. *Am J Psychiatry* 2006; 163:1934–1942
90. Fatemi SH, Stary JM, Hatsukami DK, Murphy SE: A double-blind placebo-controlled cross over trial of bupropion in smoking reduction in schizophrenia. *Schizophr Res* 2005; 76:353–356
91. Evins AE, Cather C, Culhane MA, Birnbaum A, Horowitz J, Hsieh E, Freudenreich O, Henderson DC, Schoenfeld DA, Rigotti NA, Goff DC: A 12-week double-blind, placebo-controlled study of bupropion SR added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia. *J Clin Psychopharmacol* 2007; 27:380–386
92. George TP, Vessicchio JC, Sacco KA, Weinberger AH, Dudas MM, Allen TM, Creeden CL, Potenza MN, Feingold A, Jatlow PI: A placebo-controlled trial of bupropion combined with nicotine patch for smoking cessation in schizophrenia. *Biol Psychiatry* 2008; 63:1092–1096
93. Evins AE, Cather C, Deckersbach T, Freudenreich O, Culhane MA, Olm-Shipman CM, Henderson DC, Schoenfeld DA, Goff DC, Rigotti NA: A double-blind placebo-controlled trial of bupropion sustained-release for smoking cessation in schizophrenia. *J Clin Psychopharmacol* 2005; 25:218–225
94. U.S. Food and Drug Administration: Information for Healthcare Professionals: Varenicline (marketed as Chantix) and bupropion (marketed as Zyban, Wellbutrin, and generics). <http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHealthcareProfessionals/ucm169986.htm>, 2009
95. Graeber DA, Moyers TB, Griffith G, Guajardo E, Tonigan S: A pilot study comparing motivational interviewing and an educational intervention in patients with schizophrenia and alcohol use disorders. *Community Ment Health J* 2003; 39:189–202
96. James W, Preston NJ, Koh G, Spencer C, Kisely SR, Castle DJ: A group intervention which assists patients with dual diagnosis reduce their drug use: a randomized controlled trial. *Psychol Med* 2004; 34:983–990
97. Sigmon SC, Higgins ST: Voucher-based contingent reinforcement of marijuana abstinence among individuals with serious mental illness. *J Subst Abuse Treat* 2006; 30:291–295
98. Baker A, Bucci S, Lewin TJ, Kay-Lambkin F, Constable PM, Carr VJ: Cognitive-behavioural therapy for substance use disorders in people with psychotic disorders: randomised controlled trial. *Br J Psychiatry* 2006; 188:439–448
99. Martino S, Carroll KM, Nich C, Rounsaville BJ: A randomized controlled pilot study of motivational interviewing for patients with psychotic and drug use disorders. *Addiction* 2006; 101:1479–1492